6CDE | | CRYO-EM STRUCTURE AT 3.8 A RESOLUTION OF VACCINE-ELICITED ANTIBODY VFP20.01 IN COMPLEX WITH HIV-1 ENV BG505 DS-SOSIP, AND ANTIBODIES VRC03 AND PGT122 | | Descriptor: | vFP20.01 Heavy Chain, vFP20.01 Light chain, PGT122 Heavy chain, ... | | Authors: | Acharya, P., Xu, K., Liu, K., Carragher, B., Potter, C.S., Kwong, P.D. | | Deposit date: | 2018-02-08 | | Release date: | 2018-05-16 | | Last modified: | 2019-12-18 | | Method: | ELECTRON MICROSCOPY (3.8 Å) | | Cite: | Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Nat. Med., 24, 2018
|
|
6CDI | | CRYO-EM STRUCTURE AT 3.6 A RESOLUTION OF VACCINE-ELICITED ANTIBODY VFP16.02 IN COMPLEX WITH HIV-1 ENV BG505 DS-SOSIP, AND ANTIBODIES VRC03 AND PGT122 | | Descriptor: | Glycoprotein gp41, Glycoprotein 120, PGT122 Light Chain, ... | | Authors: | Acharya, P., Xu, K., Liu, K., Carragher, B., Potter, C.S., Kwong, P.D. | | Deposit date: | 2018-02-08 | | Release date: | 2018-05-16 | | Last modified: | 2020-01-08 | | Method: | ELECTRON MICROSCOPY (3.6 Å) | | Cite: | Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Nat. Med., 24, 2018
|
|
6CDM | |
6CDO | | STRUCTURE OF VACCINE-ELICITED HIV-1 NEUTRALIZING ANTIBODY VFP16.02 IN COMPLEX WITH HIV-1 FUSION PEPTIDE RESIDUE 512-519 | | Descriptor: | vFP16.02 Fab heavy chain, vFP16.02 Fab light chain, HIV-1 fusion peptide 512-519, ... | | Authors: | Xu, K., Liu, K., Kwong, P.D. | | Deposit date: | 2018-02-08 | | Release date: | 2018-05-16 | | Last modified: | 2018-06-20 | | Method: | X-RAY DIFFRACTION (2.099 Å) | | Cite: | Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Nat. Med., 24, 2018
|
|
6CDP | | VACCINE-ELICITED HIV-1 NEUTRALIZING ANTIBODY VFP20.01 IN COMPLEX WITH HIV-1 FUSION PEPTIDE RESIDUE 512-519 | | Descriptor: | vFP20.01 Fab heavy chain, vFP20.01 Fab light chain, HIV-1 fusion peptide 512-519, ... | | Authors: | Xu, K., Liu, K., Kwong, P.D. | | Deposit date: | 2018-02-08 | | Release date: | 2018-05-16 | | Last modified: | 2018-06-20 | | Method: | X-RAY DIFFRACTION (2.456 Å) | | Cite: | Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Nat. Med., 24, 2018
|
|
4XT9 | | RORGAMMA (263-509) COMPLEXED WITH GSK2435341A AND SRC2 | | Descriptor: | Nuclear receptor ROR-gamma, LYS-ILE-LEU-HIS-ARG-LEU-LEU-GLN, N-[4-(2,5-dichlorophenyl)-5-phenyl-1,3-thiazol-2-yl]-2-[4-(ethylsulfonyl)phenyl]acetamide, ... | | Authors: | Wang, Y., Ma, Y. | | Deposit date: | 2015-01-23 | | Release date: | 2015-08-12 | | Last modified: | 2015-09-16 | | Method: | X-RAY DIFFRACTION (2.25 Å) | | Cite: | Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent ROR gamma t inverse agonists
Bioorg.Med.Chem., 23, 2015
|
|
5Z4Y | |
5Z4Z | |
5Z50 | | CRYSTAL STRUCTURE OF PACYSB REGULATORY DOMAIN | | Descriptor: | Cys regulon transcriptional activator, SULFATE ION, GLYCEROL | | Authors: | Yang, C., Liang, H., Gan, J. | | Deposit date: | 2018-01-15 | | Release date: | 2019-01-23 | | Last modified: | 2019-08-14 | | Method: | X-RAY DIFFRACTION (2.206 Å) | | Cite: | Molecular insights into the master regulator CysB-mediated bacterial virulence in Pseudomonas aeruginosa.
Mol.Microbiol., 111, 2019
|
|
5ZKP | | CRYSTAL STRUCTURE OF THE HUMAN PLATELET-ACTIVATING FACTOR RECEPTOR IN COMPLEX WITH SR 27417 | | Descriptor: | Platelet-activating factor receptor,Flavodoxin,Platelet-activating factor receptor, N1,N1-dimethyl-N2-[(pyridin-3-yl)methyl]-N2-{4-[2,4,6-tri(propan-2-yl)phenyl]-1,3-thiazol-2-yl}ethane-1,2-diamine, FLAVIN MONONUCLEOTIDE | | Authors: | Cao, C., Zhao, Q., Zhang, X.C., Wu, B. | | Deposit date: | 2018-03-25 | | Release date: | 2018-06-20 | | Method: | X-RAY DIFFRACTION (2.81 Å) | | Cite: | Structural basis for signal recognition and transduction by platelet-activating-factor receptor.
Nat. Struct. Mol. Biol., 25, 2018
|
|
5ZKQ | | CRYSTAL STRUCTURE OF THE HUMAN PLATELET-ACTIVATING FACTOR RECEPTOR IN COMPLEX WITH ABT-491 | | Descriptor: | Platelet-activating factor receptor,Endolysin,Endolysin,Platelet-activating factor receptor, 4-ethynyl-3-{3-fluoro-4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]benzene-1-carbonyl}-N,N-dimethyl-1H-indole-1-carboxamide, (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate, ... | | Authors: | Cao, C., Zhao, Q., Zhang, X.C., Wu, B. | | Deposit date: | 2018-03-25 | | Release date: | 2018-06-20 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Structural basis for signal recognition and transduction by platelet-activating-factor receptor.
Nat. Struct. Mol. Biol., 25, 2018
|
|
6JN2 | | CRYSTAL STRUCTURE OF THE COILED-COIL DOMAINS OF HUMAN DOT1L IN COMPLEX WITH AF10 | | Descriptor: | Protein AF-10, Histone-lysine N-methyltransferase, H3 lysine-79 specific | | Authors: | Song, X., Wang, M., Yang, N., Xu, R.M. | | Deposit date: | 2019-03-13 | | Release date: | 2019-09-18 | | Last modified: | 2019-10-16 | | Method: | X-RAY DIFFRACTION (3.6 Å) | | Cite: | A higher-order configuration of the heterodimeric DOT1L-AF10 coiled-coil domains potentiates their leukemogenenic activity.
Proc.Natl.Acad.Sci.USA, 116, 2019
|
|
6BR1 | | TUBULIN-RB3_SLD-TTL IN COMPLEX WITH HETEROCYCLIC PYRIMIDINE COMPOUND 4A | | Descriptor: | Tubulin alpha-1B chain, Tubulin beta-2B chain, Stathmin-4, ... | | Authors: | Kumar, G., Wang, Y., Li, W., White, S.W. | | Deposit date: | 2017-11-29 | | Release date: | 2018-06-27 | | Last modified: | 2019-12-04 | | Method: | X-RAY DIFFRACTION (2.304 Å) | | Cite: | Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
J. Med. Chem., 61, 2018
|
|
6BRF | | TUBULIN-RB3_SLD-TTL IN COMPLEX WITH HETEROCYCLIC PYRIMIDINE COMPOUND 4B | | Descriptor: | Tubulin alpha-1B chain, Tubulin beta-2B chain, Stathmin-4, ... | | Authors: | Kumar, G., Wang, Y., Li, W., White, S.W. | | Deposit date: | 2017-11-30 | | Release date: | 2018-06-27 | | Last modified: | 2019-12-04 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
J. Med. Chem., 61, 2018
|
|
6BRY | | TUBULIN-RB3_SLD-TTL IN COMPLEX WITH HETEROCYCLIC PYRIMIDINE COMPOUND 6A | | Descriptor: | Tubulin alpha-1B chain, Tubulin beta-2B chain, Stathmin-4, ... | | Authors: | Kumar, G., Wang, Y., Li, W., White, S.W. | | Deposit date: | 2017-12-01 | | Release date: | 2018-06-27 | | Last modified: | 2019-12-04 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
J. Med. Chem., 61, 2018
|
|
6BS2 | | TUBULIN-RB3_SLD-TTL IN COMPLEX WITH HETEROCYCLIC PYRIMIDINE COMPOUND 8B | | Descriptor: | Tubulin alpha-1B chain, Tubulin beta-2B chain, Stathmin-4, ... | | Authors: | Kumar, G., Wang, Y., Li, W., White, S.W. | | Deposit date: | 2017-12-01 | | Release date: | 2018-06-27 | | Last modified: | 2019-12-04 | | Method: | X-RAY DIFFRACTION (2.65 Å) | | Cite: | Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
J. Med. Chem., 61, 2018
|
|
5VZ2 | |
5W18 | | STAPHYLOCOCCUS AUREUS CLPP IN COMPLEX WITH (S)-N-((2R,6S,8AS,14AS,20S,23AS)-2,6-DIMETHYL-5,8,14,19,23-PENTAOXOOCTADECAHYDRO-1H,5H,14H,19H-PYRIDO[2,1-I]DIPYRROLO[2,1-C:2',1'-L][1]OXA[4,7,10,13]TETRAAZACYCLOHEXADECIN-20-YL)-3-PHENYL-2-(3-PHENYLUREIDO)PROPANAMIDE | | Descriptor: | ATP-dependent Clp protease proteolytic subunit, 9V7-PHE-SER-PRO-YCP-ALA-MP8 | | Authors: | Lee, R.E., Griffith, E.C. | | Deposit date: | 2017-06-02 | | Release date: | 2017-08-09 | | Last modified: | 2019-12-11 | | Method: | X-RAY DIFFRACTION (2.44 Å) | | Cite: | Ureadepsipeptides as ClpP Activators.
Acs Infect Dis., 2019
|
|
4ZN2 | |
3UPR | | HLA-B*57:01 COMPLEXED TO PEP-V AND ABACAVIR | | Descriptor: | HLA class I histocompatibility antigen, B-57 alpha chain, pep-V, ... | | Authors: | Pompeu, Y.A., Ostrov, D.A. | | Deposit date: | 2011-11-18 | | Release date: | 2012-06-13 | | Last modified: | 2012-11-14 | | Method: | X-RAY DIFFRACTION (1.999 Å) | | Cite: | Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire.
Proc.Natl.Acad.Sci.USA, 109, 2012
|
|
5NAR | |
5NAT | |
5NAW | | COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (1R,3S,5R)-2-AZA-BICYCLO[3.1.0]HEXANE-2,3-DICARBOXYLIC ACID 2-[(1-CARBAMOYL-1H-INDOL-3-YL)-AMIDE] 3-[(3-TRIFLUOROMETHOXY-PHENYL)-AMIDE] | | Descriptor: | Complement factor D, (1~{R},3~{S},5~{R})-~{N}2-(1-aminocarbonylindol-3-yl)-~{N}3-[3-(trifluoromethyloxy)phenyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxamide | | Authors: | Mac Sweeney, A., Ostermann, N. | | Deposit date: | 2017-02-28 | | Release date: | 2017-06-28 | | Last modified: | 2017-07-26 | | Method: | X-RAY DIFFRACTION (1.25 Å) | | Cite: | Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
J. Med. Chem., 60, 2017
|
|
5NB6 | | COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (2S,4S)-4-AMINO-PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-[(1-CARBAMOYL-1H-INDOL-3-YL)-AMIDE] 2-[(3-TRIFLUOROMETHOXY-PHENYL)-AMIDE] | | Descriptor: | Complement factor D, (2~{S},4~{S})-~{N}1-(1-aminocarbonylindol-3-yl)-4-azanyl-~{N}2-[3-(trifluoromethyloxy)phenyl]pyrrolidine-1,2-dicarboxamide | | Authors: | Mac Sweeney, A., Ostermann, N. | | Deposit date: | 2017-03-01 | | Release date: | 2017-06-28 | | Last modified: | 2017-07-26 | | Method: | X-RAY DIFFRACTION (1.75 Å) | | Cite: | Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
J. Med. Chem., 60, 2017
|
|
5NB7 | | COMPLEMENT FACTOR D | | Descriptor: | Complement factor D, DIMETHYL SULFOXIDE, 1-[2-[(1~{R},3~{S},5~{R})-3-[(6-bromanylpyridin-2-yl)carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxidanylidene-ethyl]indazole-3-carboxamide | | Authors: | Mac Sweeney, A., Ostermann, N. | | Deposit date: | 2017-03-01 | | Release date: | 2017-06-28 | | Last modified: | 2017-07-26 | | Method: | X-RAY DIFFRACTION (1.33 Å) | | Cite: | Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
J. Med. Chem., 60, 2017
|
|
